Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of four systematic review(s)/meta-analysis(es). ^[1-4]
• Caplacizumab significantly reduced all-cause mortality in TTP patients in some systematic reviews, although one review reported a nonsignificant reduction in mortality risk (RR (relative risk) 0.21; 95% CI (confidence interval) 0.05-1.74 in RCTs). Another review found no significant difference in mortality between caplacizumab and placebo (RR 0.56; 95% CI 0.18-1.72).
• Caplacizumab was associated with a significant reduction in refractory iTTP and exacerbation risks, while shortening the time to platelet count normalization (WMD -1.18; 95% CI -2.55 to -0.19), plasma exchange time (WMD -2.97; 95% CI -4.44 to -1.50), and hospital stay (WMD -2.88; 95% CI -4.56 to -1.21). However, it increased the risk of relapse in some studies.
• Caplacizumab was associated with an increased risk of bleeding in randomized controlled trials (RR 1.37, 95% CI 1.06-1.77), though this risk was not significantly elevated in observational studies (RR 7.10, 95% CI 0.90-56.14).
• There were no significant differences in major thrombotic events compared to standard treatment (RR 1.01, 95% CI 0.65-1.57).
• The studies focused on patients with thrombotic thrombocytopenic purpura (TTP), including acquired and immune types, and demonstrated that caplacizumab was effective in reducing refractory TTP and improving time to response. No specific subgroup differences related to age, gender, or comorbid conditions were reported.